OmniAb, Inc.

NASDAQ:OABI

Biotechnology

Healthcare
$5.08 +7.88%

+$0.16 today

Market cap
$740.97M
Beta
1.15
P/E (TTM)
-5.2
EPS (TTM)
-$0.42
52W Low $1.30High $2.79

Volume 1.22M

Average 0.67M

OABI Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

OmniAb, Inc.NASDAQ: OABI

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $6M, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $18.66M.

Context

  • Cost of revenue amounted to 118.2% of revenue in FY2025, up 118.2 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $6M or moves back toward the trailing-twelve-month quarterly average of $4.67M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6M-22.2% QoQ
Last fiscal yearDec 2025
$22.06M— YoY
LTMMar 2026
$18.66M— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
22.06M USD
Year-over-year change
—

Cost of Revenue vs competitors

How OABI compares with its peers on the latest reported figures

  • OABI's LTM Mar 2026 cost of revenue of $18.66M is the 3rd highest of the 4 companies compared; the peer median is $26.01M.
  • Cost of revenue amounts to 64.5% of revenue for OABI, versus a peer median of 30.1%.
OABI Competitors Peer median
Cost of Revenue for OABI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGNXMacroGenics, Inc.LTM Mar 2026$47.23M -18.4%+80.2%30.1%
ABSIAbsci CorporationLTM Mar 2026$26.01M -49.9%-41.6%1416.9%
OABIOmniAb, Inc.LTM Mar 2026$18.66M ——64.5%
STROSutro Biopharma, Inc.LTM Mar 2026$1.28M -28.6%-4.0%1.3%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding OABI) $26.01M-28.6%-4.0%30.1%

Competitors are the stored peer set for OABI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue34.75M59.08M34.16M26.39M18.67M
Cost of Revenue000022.06M
Gross Profit34.75M59.08M34.16M26.39M(3.39M)
Gross Margin100.0%100.0%100.0%100.0%-18.2%
Research & Development39.23M48.36M56.53M55.11M47.75M
Selling, General & Admin16.95M24.9M33.31M30.74M29.22M
Operating Expenses70.36M85.73M103.58M100.89M68.13M
Depreciation & Amortization16.25M18.25M19.5M23.58M21.75M
EBITDA(18.09M)(7.81M)(44.87M)(47.83M)(44.54M)
EBITDA Margin-52.1%-13.2%-131.3%-181.2%-238.6%
Operating Income(35.61M)(26.65M)(69.42M)(74.5M)(71.52M)
Operating Margin-102.5%-45.1%-203.2%-282.3%-383.1%
Interest Income0587K5.06M3.11M2.66M
Interest Expense7K0000
Other Income / Expenses1.26M587K5.06M3.09M5.22M
Income Before Tax(34.35M)(26.06M)(64.36M)(71.41M)(66.29M)
Pre-Tax Margin-98.9%-44.1%-188.4%-270.6%-355.2%
Income Tax Expense(7.31M)(3.73M)(13.74M)(9.38M)(1.52M)
Net Income(27.04M)(22.33M)(50.62M)(62.03M)(64.78M)
Net Margin-77.8%-37.8%-148.2%-235.1%-347.0%
EPS (Basic)(0.24)(0.26)(0.51)(0.61)(0.57)
EPS (Diluted)(0.24)(0.26)(0.51)(0.61)(0.57)
Weighted Avg Shares114.82M85.32M99.68M102.37M113.64M
Weighted Avg Shares (Diluted)114.82M85.32M99.68M102.37M113.64M

OmniAb, Inc.

NASDAQ:OABI

Intrinsic Alpha fair value

Locked

Current Price

$5.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.